Diffuse Scleroderma clinical trials at UCSF
2 in progress, 1 open to eligible people
Diffuse scleroderma is a serious disease that makes skin tight and can damage the lungs and heart. UCSF is running studies of a new cell-based therapy to measure safety and side effects. UCSF is recording lab results and breathing tests in other trials to monitor organ health.
Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-65
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
San Francisco, California and other locations
BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
San Francisco, California and other locations
Last updated: